Cargando…
MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) is the most lethal renal cancer. An overwhelming increase of patients experience tumor progression and unfavorable prognosis. However, the molecular events underlying ccRCC tumorigenesis and metastasis remain unclear. Therefore, uncovering the unde...
Autores principales: | Luo, Li, Wei, Denghui, Pan, Yihui, Wang, Qiu‐Xia, Feng, Jian‐Xiong, Yu, Bing, Kang, Tiebang, Luo, Junhang, Yang, Jiefeng, Gao, Song |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354417/ https://www.ncbi.nlm.nih.gov/pubmed/37378422 http://dx.doi.org/10.1002/cac2.12428 |
Ejemplares similares
-
The MFN1 and MFN2 mitofusins promote clustering between mitochondria and peroxisomes
por: Huo, Yinbo, et al.
Publicado: (2022) -
The mitochondrial fusion-associated protein MFN2 can be used as a novel prognostic molecule for clear cell renal cell carcinoma
por: Zhang, Bin, et al.
Publicado: (2023) -
Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma
por: Liao, Zhuangyao, et al.
Publicado: (2021) -
An Aging and Senescence-Related Gene Signature for Prognosis Prediction in Clear Cell Renal Cell Carcinoma
por: Li, Jiaying, et al.
Publicado: (2022) -
SYNE1 mutation may enhance the response to immune checkpoint blockade therapy in clear cell renal cell carcinoma patients
por: Li, Pengju, et al.
Publicado: (2020)